| Literature DB >> 34854928 |
Gudula J A M Boon1, Yvonne M Ende-Verhaar2, Ludo F M Beenen3, Johan Coolen4, Marion Delcroix5, Marek Golebiowski6, Menno V Huisman2, Albert T A Mairuhu7, Lilian J Meijboom8, Saskia Middeldorp9, Piotr Pruszczyk10, Cornelis J van Rooden11, Anton Vonk Noordegraaf12, Lucia J M Kroft13, Frederikus A Klok2.
Abstract
OBJECTIVES: Closer reading of computed tomography pulmonary angiography (CTPA) scans of patients presenting with acute pulmonary embolism (PE) may identify those at high risk of developing chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to validate the predictive value of six radiological predictors that were previously proposed.Entities:
Keywords: Chronis thromboembolic pulmonary hypertension; Computed tomography angiography; Pulmonary artery; Pulmonary embolism; Pulmonary hypertension
Mesh:
Year: 2021 PMID: 34854928 PMCID: PMC8921171 DOI: 10.1007/s00330-021-08364-0
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 7.034
Fig. 1CTPA image showing the six radiological predictors of CTEPH in addition to RV/LV diameter ratio of > 1.0. Abbreviations: CTPA, computed tomography pulmonary angiography; CTEPH, chronic thromboembolic pulmonary hypertension; RV, right ventricle; LV, left ventricle
Baseline characteristics of study participants
| Patients with available index CTPAs ( | |
|---|---|
| Age (mean ± SD) | 56 (16) |
| Male sex ( | 167 (49) |
| BMI (mean ± SD) | 28 (5.9) |
| Unprovoked PE ( | 188 (55) |
| High-risk PE* ( | 9 (2.6) |
| A prior history of VTE ( | 71 (21) |
| Onset of symptoms > 2 weeks before index PE diagnosis ( | 73 (21) |
| Anaemia | 71 (21) |
| COPD/asthma | 38 (11) |
| Active malignancy# | 31 (9.1) |
| Diabetes mellitus | 24 (7.0) |
| Coronary artery disease | 22 (6.5) |
| Rheumatic disease^ | 15 (4.4) |
| Hypothyroidism | 14 (4.1) |
| Known antiphospholipid antibodies | 5 (1.5) |
| Interstitial lung disease | 4 (1.2) |
| Inflammatory bowel disease | 4 (1.2) |
| Major vasculitis syndromes | 2 (0.6) |
| Prior infected pacemaker leads | 1 (0.3) |
| Splenectomy | 1 (0.3) |
| DOAC | 233 (68) |
| VKA | 87 (26) |
| LMWH | 29 (8.5) |
Note:
*According to the 2019 European Society of Cardiology Guidelines on Acute PE
Active malignancy was defined as follows: diagnosis of cancer within 6 months prior to enrolment, any treatment for cancer within the previous 6 months or recurrent metastatic cancer
^Rheumatic disease was defined as follows: known rheumatic arthritis, osteoarthritis, connective tissue disease, systemic lupus erythematosus, ankylosing spondylitis or Sjögren syndrome
Abbreviations: PE, pulmonary embolism; SD, standard deviation; BMI, body mass index; VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant. Anaemia was defined as: males < 8.5 mmol/L or < 13.5 g/dL; females < 7.5 mmol/L or < 12.0 g/dL
Prevalence of radiological signs of chronic thrombi and PH, and of the six predefined independent predictors for a future CTEPH diagnosis after acute PE
| Total study population ( | CTEPH diagnosis confirmed ( | CTEPH ruled out ( | |
|---|---|---|---|
| Signs of chronic thrombi present ( | 74 (22) | 6 (67) | 68 (20) |
| Signs of PH present ( | 104 (30) | 8 (89) | 96 (29) |
| Intravascular webs | 41 (12) | 5 (56) | 36 (11) |
| Arterial retraction | 41 (12) | 5 (56) | 36 (11) |
| Dilated bronchial arteries | 24 (7.0) | 3 (33) | 21 (6) |
| Dilatation of the pulmonary trunk | 119 (35) | 7 (78) | 112 (34) |
| RV hypertrophy | 19 (5.6) | 2 (22) | 17 (5) |
| Flattening of the interventricular septum | 84 (25) | 3 (33) | 81 (24) |
Notes: *Concerns direct and indirect signs of chronic RV overload
Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; OR, odds ratio; RV, right ventricle; 95%CI, 95% confidence interval
Results of the assessment of radiological signs of CTEPH in patients ultimately diagnosed with CTEPH versus those in whom CTEPH was ruled out after 2-year follow-up
| CTEPH diagnosis confirmed, | CTEPH ruled out, | Univariate analysis (OR, 95%CI) | Sensitivity (%, 95%CI) | Specificity (%, 95%CI) | PPV (%, 95%CI) | NPV (%, 95%CI) | Positive likelihood ratio (95%CI) | Negative likelihood ratio (95%CI) | |
|---|---|---|---|---|---|---|---|---|---|
| Presence of ≥ 3 of 6 predictors of CTEPH | 4 (44) | 33 (10) | 7.2 (1.9–28) | 44 (14–79) | 90 (86–93) | 11 (5.2–21) | 98 (97–99) | 4.5 (2.0–9.9) | 0.62 (0.34–1.1) |
| Overall judgment: CTEPH present | 8 (89) | 19 (5.7) | 132 (16–1109) | 89 (52–99.7) | 94 (91–97) | 30 (20–41) | 99.7 (98–99.9) | 16 (9.5–25) | 0.12 (0.0–0.8) |
Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; OR, odds ratio; 95%CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value
Results of the assessment of CPTA reading in subgroups of the InShape II study population while completing the InShape II algorithm 3–6 months after acute PE
| Numbers ( | Sensitivity | Specificity | PPV | NPV | Numbers ( | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical pre-test probability* | ||||||||||
| Presence of ≥ 3 of 6 predictors of CTEPH | 13 (5.3) | 50 (1.3–99) | 95 (92–97) | 7.7 (1.8–27) | 99.6 (98–99.9) | 24 (25) | 43 (9.9–82) | 76 (66–85) | 13 (5.3–27) | 94 (90–97) |
| Overall judgment: CTEPH present | 9 (3.7) | 100 (16–100) | 97 (94–99) | 22 (12–37) | 100 | 18 (19) | 86 (42–99.6) | 87 (78–93) | 33 (21–48) | 99 (93–99.7) |
| Presence of symptoms suggestive of CTEPH despite low clinical pre-test probability # | ||||||||||
| Presence of ≥ 3 of 6 predictors of CTEPH | 34 (12) | 43 (9.9–82) | 89 (84–92) | 8.8 (3.7–20) | 98 (97–99) | 3 (4.9) | 50 (91.3–99) | 97 (88–99.6) | 33 (6.7–78) | 98 (93–99.5) |
| Overall judgment: CTEPH present | 25 (8.9) | 86 (42–99.6) | 93 (89–96) | 24 (16–35) | 99.6 (98–99.9) | 2 (3.3) | 100 (16–100) | 100 (94–100) | 100 | 100 |
| Sex | ||||||||||
| Presence of ≥ 3 of 6 predictors of CTEPH | 21 (13) | 43 (9.9–82) | 89 (83–93) | 14 (6.0–30) | 97 (95–99) | 16 (9.2) | 50 (1.3–99) | 91 (86–95) | 6.3 (1.5–22) | 99 (98–99.8) |
| Overall judgment: CTEPH present | 16 (9.6) | 100 (59–100) | 94 (90–97) | 44 (29–59) | 100 | 11 (6.3) | 50 (1.3–99) | 94 (90–97) | 9.1 (2.2–31) | 99 (98–99.897) |
Notes: Values of diagnostic accuracy and predictive values are denoted as percentage, 95%CI
*Based on a clinical CTEPH prediction score of > 6.[11; 13]
# Based on a clinical CTEPH prediction score of < 7. [11; 13]